Monte Rosa Therapeutics(GLUE) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Phase 1/2 study of GSPT1-directed MGD MRT-2359 advancing in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients; additional results expected by year-end Strong cash position expected to fund operations through 2028, enabling multiple anticipated proof-of- concept clinical readouts across the portfolio BOSTON, Mass., Nov. 6, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-b ...